Our group has also recently shown the presence of immunoreactive human chymase in DVT derived from patients and have also reported that recombinant CMA-1 inactivates purified human plasmin’s hydrolytic properties in a chymase inhibitor-sensitive manner (15). This evidence concerns the gene PLG and deep vein thrombosis.